Biotechnology and Pharmaceuticals

March 18, 2021

Buy ($175)

Companies covered: Arcturus Therapeutics Ltd. (NASDAQ:ARCT), Vaxart (NASDAQ:VXRT), Veru (NASDAQ:VERU), Moderna (NASDAQ:MRNA), Pfizer, Inc. (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Atreca (NASDAQ:BCEL), BioCardia Inc. (NASDAQ:BCDA), Forte Biosciences Inc. (NASDAQ:FBRX), Caladrius Biosciences Inc. (NASDAQ:CLBS), Medicenna Therapeutics Corp. (NASDAQ:MDNA), SpringWorks Therapeutics (NASDAQ:SWTX), bluebird bio, Inc. (NASDAQ:BLUE), AVROBIO (NASDAQ:AVRO), Blueprint Medicines Corp. (NASDAQ:BPMC), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Argenx SE (ADR) (NASDAQ:ARGX), Magenta Therapeutics Inc. (NASDAQ:MGTA), Scholar Rock Holding Corp. (NASDAQ:SRRK), Orchard Therapeutics PLC – ADR (NASDAQ:ORTX), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH), Ortho Regenerative Technologies Inc. (OTCMKTS:ORTIF), Lantern Pharma Inc. (NASDAQ:LTRN), Kintara Therapeutics Inc. (NASDAQ:KTRA), DarioHealth Corp. (NASDAQ:DRIO), AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ:ANPC), BiOasis Technologies Inc. (OTCMKTS:BIOAF), Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX), electroCore, Inc. (NASDAQ:ECOR), MiMedx Group, Inc (NASDAQ:MDXG), Heat Biologics, Inc. (NASDAQ:HTBX), Achieve Life Sciences (NASDAQ:ACHV), Zoom Video Communications (NASDAQ:ZM), Amazon.com, Inc. (NASDAQ:AMZN), Walt Disney Company (The) (NYSE:DIS), Netflix, Inc. (NASDAQ:NFLX), Amarin Corporation PLC (NASDAQ:AMRN), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Durect Corporation (NASDAQ:DRRX), Cancer Genetics, Inc. (NASDAQ:CGIX), Quick-Med Technologies Inc. (OTCMKTS:QMDT), VolitionRX Limited (NYSEAMERICAN:VNRX), NovelStem International Corp. (OTCMKTS:NSTM)

Biotechnology and Pharmaceuticals

September 21, 2020

Buy ($175)

Companies covered: Moderna (NASDAQ:MRNA), Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Novavax, Inc. (NASDAQ:NVAX), Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), Vir Biotechnology (NASDAQ:VIR), Emergent Biosolutions, Inc. (NYSE:EBS), Oxford BioMedica plc (OTCMKTS:OXBDF), Luminex Corporation (NASDAQ:LMNX), Quidel Corporation (NASDAQ:QDEL), GlaxoSmithKline PLC (NYSE:GSK), AstraZeneca PLC (NASDAQ:AZN), Sanofi (NYSE:SNY), Pfizer, Inc. (NYSE:PFE), BioNTech SE (ADR) (NASDAQ:BNTX), Patterson Companies, Inc. (NASDAQ:PDCO), Henry Schein, Inc. (NASDAQ:HSIC), Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), Johnson & Johnson (NYSE:JNJ), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Endo International plc (NASDAQ:ENDP), Eli Lilly and Company (NYSE:LLY), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Zoetis Inc. (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Merck & Company, Inc. (NYSE:MRK), Amazon.com, Inc. (NASDAQ:AMZN), Covetrus (NASDAQ:CVET), Chewy (NYSE:CHWY), Abivax (OTCMKTS:AAVXF), Organicell Regenerative Medicine, Inc. (OTCMKTS:BPSR), Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), Fate Therapeutics, Inc. (NASDAQ:FATE), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Applied Genetic Technologies Corporation (NASDAQ:AGTC), Epizyme, Inc. (NASDAQ:EPZM), Blueprint Medicines Corp. (NASDAQ:BPMC), Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), Novartis AG (NYSE:NVS), Beam Therapeutics (NASDAQ:BEAM), Generation Bio Co. (NASDAQ:GBIO), SpringWorks Therapeutics (NASDAQ:SWTX), Argenx SE (ADR) (NASDAQ:ARGX), Gilead Sciences, Inc. (NASDAQ:GILD), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Immunomedics, Inc. (NASDAQ:IMMU), aTyr Pharma (NASDAQ:LIFE), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), NeuBase Therapeutics, Inc. (NASDAQ:NBSE), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Wave Life Sciences Ltd (NASDAQ:WVE), Catabasis Pharmaceuticals Inc (NASDAQ:CATB), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), AbbVie Inc. (NYSE:ABBV), Bristol-Myers Squibb Company (NYSE:BMY), Seelos Therapeutics, Inc. (NASDAQ:SEEL), Kazia Therapeutics Limited (NASDAQ:KZIA), Akebia Therapeutics, Inc. (NASDAQ:AKBA), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), 22nd Century Group, Inc. (NYSEAMERICAN:XXII), EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG), Boomer Holdings, Inc. (OTCMKTS:BOMH)

Medical Devices

June 12, 2020

Buy ($175)

Companies covered: Medtronic, Inc. (NYSE:MDT), Intuitive Surgical, Inc. (NASDAQ:ISRG), Edwards Lifesciences Corporation (NYSE:EW), DexCom, Inc. (NASDAQ:DXCM), Abbott Laboratories (NYSE:ABT), Boston Scientific Corporation (NYSE:BSX), ViewRay Inc. (NASDAQ:VRAY), ResMed Inc. (NYSE:RMD), Shockwave Medical (NASDAQ:SWAV), Inspire Medical Systems (NYSE:INSP), Becton, Dickinson and Company (NYSE:BDX), Hologic, Inc. (NASDAQ:HOLX), Globus Medical, Inc. (NYSE:GMED), Tactile Systems Technology, Inc. (NASDAQ:TCMD), AxoGen, Inc. (NASDAQ:AXGN), NeuroMetrix, Inc. (NASDAQ:NURO), Bio-Techne Corp (NASDAQ:TECH), Stereotaxis, Inc. (NASDAQ:STXS), Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), Tandem Diabetes Care, Inc. (NASDAQ:TNDM), Motus GI Holdings, Inc. (NASDAQ:MOTS)

Biotechnology and Pharmaceuticals

March 20, 2020

Buy ($175)

Companies covered: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Allogene Therapeutics (NASDAQ:ALLO), CRISPR Therapeutics AG (NASDAQ:CRSP), Precision BioSciences (NASDAQ:DTIL), Celyad SA (ADR) (NASDAQ:CYAD), Cellectis S.A. (NASDAQ:CLLS), Pfizer, Inc. (NYSE:PFE), Sangamo Therapeutics, Inc. (NASDAQ:SGMO), Selecta Biosciences Inc (NASDAQ:SELB), Horizon Pharma plc (NASDAQ:HZNP), Calyxt (NASDAQ:CLXT), Amgen Inc. (NASDAQ:AMGN), Novartis AG (NYSE:NVS), Allergan, Inc. (NYSE:AGN), AbbVie Inc. (NYSE:ABBV), Bristol-Myers Squibb Company (NYSE:BMY), H. Lundbeck A/S (ADR) (OTCMKTS:HLUYY), Karuna Therapeutics (NASDAQ:KRTX), Satsuma Pharmaceuticals (NASDAQ:STSA), BioLife Solutions, Inc. (NASDAQ:BLFS), Brooks Automation, Inc. (NASDAQ:BRKS), Catalent, Inc. (NYSE:CTLT), CryoPort Inc. (NASDAQ:CYRX), Repligen Corporation (NASDAQ:RGEN), Bio-Techne Corp (NASDAQ:TECH), Biogen Inc. (NASDAQ:BIIB), Denali Therapeutics (NASDAQ:DNLI), Amicus Therapeutics, Inc. (NASDAQ:FOLD), WuXi Biologics Cayman (OTCMKTS:WXIBF), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Rocket Pharmaceuticals (NASDAQ:RCKT), Novocure Ltd. (NASDAQ:NVCR), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Moderna (NASDAQ:MRNA), Arcturus Therapeutics Ltd. (NASDAQ:ARCT), SCYNEXIS, Inc. (NASDAQ:SCYX), Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), Omeros Corporation (NASDAQ:OMER), Medicenna Therapeutics Corp. (NASDAQ:MDNA), Veru (NASDAQ:VERU), Chiasma (NASDAQ:CHMA), Atreca (NASDAQ:BCEL), Monopar Therapeutics (NASDAQ:MNPR), Vaxart (NASDAQ:VXRT), CEL-SCI Corporation (NYSEAMERICAN:CVM), ProMIS Neurosciences (TSE:PMN), Fortress Biotech, Inc. (NASDAQ:FBIO), Achieve Life Sciences (NASDAQ:ACHV), AzurRx BioPharma (NASDAQ:AZRX), Passage Bio (NASDAQ:PASG), Pressure BioSciences Inc. (OTCMKTS:PBIO), Sensus Healthcare (NASDAQ:SRTS), Nanobiotix (EPA:NANO), Protagonist Therapeutics, Inc. (NASDAQ:PTGX), Quick-Med Technologies Inc. (OTCMKTS:QMDT), RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI), Mesoblast Limited (NASDAQ:MESO), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

Biotechnology and Pharmaceuticals

October 04, 2019

Buy ($175)

Companies covered: Spark Therapeutics, Inc. (NASDAQ:ONCE), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Audentes Therapeutics (NASDAQ:BOLD), Novartis AG (NYSE:NVS), bluebird bio, Inc. (NASDAQ:BLUE), Novocure Ltd. (NASDAQ:NVCR), Mallinckrodt plc (NYSE:MNK), Endo International plc (NASDAQ:ENDP), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Insys Therapeutics, Inc. (NASDAQ:INSY), Johnson & Johnson (NYSE:JNJ), Recro Pharma, Inc. (NASDAQ:REPH), Flexion Therapeutics, Inc. (NASDAQ:FLXN), Galapagos NV (NASDAQ:GLPG), Amneal Pharmaceuticals (NYSE:AMRX), Indivior PLC (OTCMKTS:IZQVF), Reckitt Benckiser Group plc (OTCMKTS:RBGPF), Quick-Med Technologies Inc. (OTCMKTS:QMDT), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Oncternal Therapeutics, Inc. (NASDAQ:ONCT), RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI), BioXcel Therapeutics, Inc. (NASDAQ:BTAI), Phio Pharmaceuticals Corp. (NASDAQ:PHIO), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)